Showing results (231-240 of 678) with videos related to

Sort By:
Pageof 68
Applied Immunohistochemistry & Molecular Morphology : AIMM|January 13, 2010
The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphomaAashiyana F Koreishi, Adam J Saenz, Dan O Persky, et al.
JCO Clinical Cancer Informatics|July 16, 2025
Deep Learning-Based Body Composition Analysis for Outcome Prediction in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Insights From the LOTIS-2 TrialRuss A Kuker, Juan P Alderuccio, Sunwoo Han, et al.
European Journal of Biochemistry|June 1, 1997
Anti-insect toxin 5 (AaIT5) from Androctonus australisY Nakagawa, Y M Lee, E Lehmberg, et al.
Lab on a Chip|June 5, 2009
A microfluidic chip for electrochemical conversions in drug metabolism studiesM Odijk, A Baumann, W Lohmann, et al.
British Journal of Haematology|June 9, 2006
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphomaTarun Kewalramani, Andrew D Zelenetz, Julie Teruya-Feldstein, et al.
The Journal of Antimicrobial Chemotherapy|March 1, 1994
The activity of 2-substituted quinoline alkaloids in BALB/c mice infected with Leishmania donovaniA Fournet, J C Gantier, A Gautheret, et al.
Cancers|November 11, 2022
A Deep Learning-Aided Automated Method for Calculating Metabolic Tumor Volume in Diffuse Large B-Cell LymphomaRuss A Kuker, David Lehmkuhl, Deukwoo Kwon, et al.
Leukemia & Lymphoma|April 22, 2014
Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamideMary R Welch, Craig S Sauter, Matthew J Matasar, et al.
Blood Advances|June 20, 2020
KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failurePhilippe Armand, John Kuruvilla, Jean-Marie Michot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphomaA K Gopal, M A Fanale, C H Moskowitz, et al.
Pageof 68